| 18.35 0.69 (3.91%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 21.84 | 1-year : | 25.51 |
| Resists | First : | 18.7 | Second : | 21.84 |
| Pivot price | 17.44 |
|||
| Supports | First : | 16.79 | Second : | 15.61 |
| MAs | MA(5) : | 17.8 |
MA(20) : | 17.28 |
| MA(100) : | 14.24 |
MA(250) : | 10.54 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 75.7 |
D(3) : | 73 |
| RSI | RSI(14): 62.3 |
|||
| 52-week | High : | 18.7 | Low : | 4.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DFTX ] has closed It is unclear right now based on current values. 45.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 17.91 - 18 | 18 - 18.08 |
| Low: | 16.78 - 16.87 | 16.87 - 16.96 |
| Close: | 17.5 - 17.65 | 17.65 - 17.8 |
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Tue, 24 Feb 2026
Definium Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
Thu, 19 Feb 2026
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 - Business Wire
Mon, 02 Feb 2026
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Thu, 29 Jan 2026
DFTX Stock Price, News & Analysis - Stock Titan
Tue, 13 Jan 2026
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026 - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 100 (M) |
| Shares Float | 94 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 71.6 (%) |
| Shares Short | 19,510 (K) |
| Shares Short P.Month | 16,830 (K) |
| EPS | -2.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.1 % |
| Return on Equity (ttm) | -64.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -132 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -8.91 |
| PEG Ratio | 0 |
| Price to Book value | 5.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|